Combination therapy using a TNF binding protein for treating TNF-mediated diseases
AssigneeAmgen Inc.
InventorsAlison M. Bendele, Regina M. Sennello, Carl K. Edwards III
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
Claims26
A method for treating an acute or chronic inflammatory disease which comprises administering to a patient in need thereof therapeutically effective amounts of a TNF binding protein and at least one additional anti-inflammatory drug, wherein said TNF binding protein and additional anti-inflammatory drug are administered separately or in combination.
A pharmaceutical composition comprising a TNF binding protein and an additional anti-inflammatory drug.
The pharmaceutical composition wherein the anti-inflammatory drug is methotrexate.
The pharmaceutical composition wherein the anti-inflammatory drug is a fas fusion protein.
A use of an anti-inflammatory drug, other than a non-TNF binding protein, in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of a TNF binding protein.
A use of a TNF binding protein in the preparation of a medicament for treating an acute or chronic inflammatory disease in a mammal in combination with the administration of an additional anti-inflammatory drug.
Dependencies are inferred from the claim text.